Kazia Therapeutics Limited ADR [NASDAQ: KZIA] price surged by 58.04 percent to reach at $0.2.
The one-year KZIA stock forecast points to a potential upside of 73.5. The average equity rating for KZIA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Kazia Therapeutics Limited ADR [KZIA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KZIA shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KZIA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Kazia Therapeutics Limited ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on January 05, 2021, representing the official price target for Kazia Therapeutics Limited ADR stock.
The Average True Range (ATR) for Kazia Therapeutics Limited ADR is set at 0.05 The Price to Book ratio for the last quarter was 3.86, with the Price to Cash per share for the same quarter was set at 0.10.
KZIA Stock Performance Analysis:
Kazia Therapeutics Limited ADR [KZIA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.74. With this latest performance, KZIA shares gained by 54.97% in over the last four-week period, additionally plugging by 52.20% over the last 6 months – not to mention a drop of -20.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KZIA stock in for the last two-week period is set at 66.60, with the RSI for the last a single of trading hit 71.17, and the three-weeks RSI is set at 62.43 for Kazia Therapeutics Limited ADR [KZIA]. The present Moving Average for the last 50 days of trading for this stock 0.3828, while it was recorded at 0.3998 for the last single week of trading, and 0.3374 for the last 200 days.
Insight into Kazia Therapeutics Limited ADR Fundamentals:
Kazia Therapeutics Limited ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.71 and a Current Ratio set at 0.71.
Kazia Therapeutics Limited ADR [KZIA] Institutonal Ownership Details
There are presently around $1.36%, or 1.36%% of KZIA stock, in the hands of institutional investors. The top three institutional holders of KZIA stocks are: MORGAN STANLEY with ownership of 0.2 million shares, which is approximately 0.8386%. BNP PARIBAS ARBITRAGE, SNC, holding 63568.0 shares of the stock with an approximate value of $$14532.0 in KZIA stocks shares; and BNP PARIBAS ARBITRAGE, SNC, currently with $$9457.0 in KZIA stock with ownership which is approximately 0.173%.
